A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate
Completed
- Conditions
- Metastatic Breast Cancer
- Registration Number
- NCT02528747
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational, multicenter survey is designed to assess the efficacy of oral ibandronate in adults with breast cancer and metastatic bone disease. Data on the use of ibandronate in clinical practice will be collected from Hungarian patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 582
Inclusion Criteria
- Adults at least 18 years of age
- Histologically confirmed breast cancer with bone metastasis
- Receiving or indicated for the tablet formulation of ibandronate according to the summary of product characteristics (SmPC) and local labeling
Read More
Exclusion Criteria
- Contraindication to ibandronate according to SmPC
- Ongoing participation in any trial evaluating the efficacy and/or safety of ibandronate
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in bone pain according to Visual Analog Scale (VAS) score From Baseline to the end of 1 year
- Secondary Outcome Measures
Name Time Method Compliance with tablet formulation of ibandronate according to Case Report Form (CRF) questionnaire Up to approximately 1 year Incidence of adverse events Up to approximately 1 year